KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to $1.1 million.

  • Aurinia Pharmaceuticals' Interest Expenses fell 902.32% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 1140.23%. This contributed to the annual value of $4.8 million for FY2024, which is 7423.42% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Interest Expenses is $1.1 million, which was down 902.32% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Interest Expenses registered a high of $1.4 million during Q3 2023, and its lowest value of -$204000.0 during Q4 2021.
  • Its 4-year average for Interest Expenses is $971727.3, with a median of $1.1 million in 2024.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Interest Expenses soared by 174307.69% in 2024 and then crashed by 1683.55% in 2025.
  • Over the past 4 years, Aurinia Pharmaceuticals' Interest Expenses (Quarter) stood at -$204000.0 in 2021, then surged by 742.16% to $1.3 million in 2023, then dropped by 12.52% to $1.1 million in 2024, then decreased by 4.1% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.